Hepatitis B Market Outlook 2032 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

Hepatitis B Market Summary
According to DelveInsight, the Hepatitis B Virus (HBV) market is projected to register a steady compound annual growth rate (CAGR) through 2032. The substantial global prevalence of chronic hepatitis B (CHB) remains the primary driver of market expansion, prompting increased investment and research focus from pharmaceutical companies. Recent advancements have introduced novel diagnostic biomarkers that enhance the identification of CHB patients, thereby improving diagnostic precision.

DelveInsight's "Hepatitis B Market Insights, Epidemiology, and Market Forecast - 2032" report provides a comprehensive analysis of Hepatitis B, covering both historical and projected epidemiology, along with market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. The report examines emerging therapies, existing treatment approaches, market share of individual drugs, and the current and forecasted market size from 2019 to 2032. It further analyzes the prevailing treatment practices and algorithms, key market drivers and challenges, as well as unmet medical needs, to identify optimal opportunities and evaluate the growth potential within the Hepatitis B market.

To Know in detail about the Hepatitis B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis B Market Forecast - https://www.delveinsight.com/report-store/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the Hepatitis B Market Report:
• In July 2025, Gilead Sciences announced a clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
• In July 2025, GlaxoSmithKline conducted a study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
• On 12 Feb 2025 (Singapore Time), Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial. This significant progress further solidifies Lion TCR's leading position in the mRNA-based TCR-T field and brings new hope to patients with Hepatitis B virus related hepatocellular carcinoma (HCC).
• In January 2025:- Janssen Research & Development LLC:- A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection
• According to estimates provided by the Hepatitis B Foundation, National Foundation for Infectious Diseases (2018), and the CDC, the total number of chronic hepatitis B cases is estimated to be approximately 2.2 million or higher.
In 2023, the United States recorded approximately 881,700 diagnosed prevalent cases of chronic hepatitis B.
• In the European Union's four largest countries plus the United Kingdom (EU4+UK), Germany had the highest diagnosed prevalence of chronic hepatitis B, totaling approximately 175,000 cases, whereas Spain had the lowest diagnosed prevalence, with around 52,500 cases in 2023.
• Key Hepatitis B Companies: Arbutus Biopharma, GSK/Ionis Pharmaceuticals, Vir Biotechnology, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp, Brii Biosciences Limited, Vir Biotechnology, Inc., Arbutus Biopharma Corporation, Erasmus Medical Center, Daewoong Pharmaceutical Co., Ascletis Pharmaceuticals, Gilead Sciences, Fujian Akeylink Biotechnology, Chia Tai Tianqing Pharma, Janssen Research & Development, LLC, Hoffmann-La Roche, Chengdu Suncadia Medicine, Suzhou Ribo Life Science, Arbutus Biopharma Corporation, Ascentage Pharma Group, and others
• Key Hepatitis B Therapies: AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFNα, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others
• The Hepatitis B epidemiology based on gender analyzed that in 2023, there were more diagnosed prevalent cases of chronic hepatitis B (CHB) among males than females in the United States.
• The Hepatitis B market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis B pipeline products will significantly revolutionize the Hepatitis B market dynamics.
• In March 2024, Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.
• In February 2024, GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for bepirovirsen, an investigational antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB). Fast track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Hepatitis B Overview
Hepatitis B is a viral infection caused by the hepatitis B virus (HBV) that primarily affects the liver, leading to both acute and chronic disease. It is a major global health concern, transmitted through contact with infected blood, semen, or other body fluids, commonly via unprotected sexual contact, sharing of needles, or from mother to child during childbirth. Acute Hepatitis B may be asymptomatic or present with symptoms such as fever, fatigue, jaundice, dark urine, abdominal pain, and loss of appetite. While many adults can clear the infection naturally, in some cases, especially in infants and young children, it can progress to chronic Hepatitis B. Chronic infection increases the risk of developing serious complications, including cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Hepatitis B Diagnosis involves serological tests to detect HBV antigens and antibodies, as well as Hepatitis B virus DNA testing to determine viral load. Although there is no definitive cure, effective antiviral medications, such as tenofovir and entecavir, can suppress viral replication and reduce disease progression. Hepatitis B Preventive measures, including widespread vaccination, safe injection practices, and screening of blood products, have significantly reduced the incidence of Hepatitis B worldwide. Early detection and adherence to treatment are critical to improving patient outcomes.

Get a Free sample for the Hepatitis B Market Forecast, Size & Share Analysis Report @ Hepatitis B Virus Treatment Market - https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatitis B Epidemiology
In 2023, the US accounted for around 882,000 diagnosed prevalent cases of chronic hepatitis B. Among EU4 and the UK, Germany accounted for the highest diagnosed prevalence of chronic hepatitis B with approximately 175,000 cases, while Spain had the lowest diagnosed prevalence with around 52,500 cases in 2023. Japan accounted for around 20% of the total diagnosed prevalent cases of CHB in the 7MM in 2023.In 2023, the United States accounted for ~60% of the total diagnosed prevalent cases of CHB in the 7MM. In 2023, males accounted for a higher number of diagnosed prevalent cases of CHB than females in the United States.

Hepatitis B Epidemiology Segmentation:
The Hepatitis B market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Hepatitis B
• Prevalent Cases of Hepatitis B by severity
• Gender-specific Prevalence of Hepatitis B
• Diagnosed Cases of Episodic and Chronic Hepatitis B

Download the report to understand which factors are driving Hepatitis B epidemiology trends @ Hepatitis B Patient Pool and Prevalence - https://www.delveinsight.com/report-store/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatitis B Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis B market or expected to get launched during the study period. The analysis covers Hepatitis B market uptake by drugs, patient uptake by therapies, and sales of each drug.

Hepatitis B Therapies and Key Companies
• AB-729: Arbutus Biopharma
• Bepirovirsen: GSK/Ionis Pharmaceuticals
• Elebsiran: Vir Biotechnology
• GSK3965193: GlaxoSmithKline
• DA-2803: Dong-A ST Co., Ltd.
• ChAdOx1-HBV: Barinthus Biotherapeutics
• Undiluted I.V.-Hepabig inj(GC5103): GC Biopharma Corp
• PEG-IFNα: Brii Biosciences Limited
• VIR-3434: Vir Biotechnology, Inc.
• AB-729: Arbutus Biopharma Corporation
• ISA104: Erasmus Medical Center
• Vemliver tablet: Daewoong Pharmaceutical Co. LTD.
• ASC22: Ascletis Pharmaceuticals
• TAF: Gilead Sciences
• GST-HG131: Fujian Akeylink Biotechnology
• TQA3605 tablets: Chia Tai Tianqing Pharma
• JNJ-73763989: Janssen Research & Development, LLC
• Nucleos(t)ide (NUC): Hoffmann-La Roche
• HRS9950 tablets: Chengdu Suncadia Medicine
• RBD1016: Suzhou Ribo Life Science
• Imdusiran: Arbutus Biopharma Corporation
• APG-1387: Ascentage Pharma Group

Discover more about therapies set to grab major Hepatitis B market share @ Hepatitis B Drugs Market and Treatment Landscape - https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hepatitis B Market Dynamics: Drivers and Barriers

Hepatitis B Market Drivers
• High Global Prevalence of CHB: The large patient pool continues to drive demand for effective diagnostics and treatments.
• Advancements in Diagnostic Biomarkers: Introduction of novel serologic and virologic biomarkers enables earlier and more accurate diagnosis.
• Improved Screening Programs: Widespread screening, especially in high-risk populations, supports early intervention and better disease management.
• Government and WHO Vaccination Initiatives: Expanded immunization programs reduce new infections while highlighting the need for chronic disease management.
• Pharmaceutical R&D Investment: Increased focus by companies on developing novel therapies, including curative approaches.

Hepatitis B Market Barriers
• Incomplete Understanding of Virus-Host Interactions: Limited insights into immune response mechanisms hinder curative treatment development.
• Lack of Functional Cure: Current antivirals suppress replication but rarely achieve complete viral clearance.
• Underdiagnosis in Asymptomatic Cases: Many patients remain undetected until advanced stages, limiting timely treatment.
• Treatment Adherence Challenges: Long-term antiviral therapy may face compliance issues due to cost, side effects, and patient perception.
• Regional Disparities in Healthcare Access: Low- and middle-income regions often face barriers in diagnosis, treatment availability, and follow-up care.

To know more about Hepatitis B companies working in the treatment market, visit @ Hepatitis B Clinical Trials and Therapeutic Assessment - https://www.delveinsight.com/sample-request/hepatitis-b-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Hepatitis B Market Report
• Study Period: 2019-2032
• Coverage: 7MM
• Key Hepatitis B Companies: Arbutus Biopharma Corporation (NASDAQ: ABUS), GSK plc (LSE: GSK), Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), Vir Biotechnology, Inc. (NASDAQ: VIR), Dong-A ST Co., Ltd. (KRX: 170900), Barinthus Biotherapeutics plc (NASDAQ: BRNS), GC Biopharma Corp (KRX: 006280), Brii Biosciences Limited (HKEX: 2137), Erasmus Medical Center (not publicly traded), Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), Ascletis Pharma Inc. (HKEX: 1672), Gilead Sciences, Inc. (NASDAQ: GILD), Fujian Akeylink Biotechnology Co. (not publicly traded), Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical, HKEX: 1177), Janssen Research & Development, LLC (subsidiary of Johnson & Johnson, NYSE: JNJ), Hoffmann-La Roche Ltd (SWX: ROG), Chengdu Suncadia Medicine (not publicly traded), Suzhou Ribo Life Science Co., Ltd. (not publicly traded), and Ascentage Pharma Group International (HKEX: 6855).
• Key Hepatitis B Therapies: AB-729, Bepirovirsen, Elebsiran, GSK3965193, DA-2803, ChAdOx1-HBV, Undiluted I.V.-Hepabig inj(GC5103), PEG-IFNα, VIR-3434, AB-729, ISA104, Vemliver tablet, ASC22, TAF, GST-HG131, TQA3605 tablets, JNJ-73763989, Nucleos(t)ide (NUC), HRS9950 tablets, RBD1016, Imdusiran, APG-1387, and others
• Hepatitis B Therapeutic Assessment: Hepatitis B current marketed and Hepatitis B emerging therapies
• Hepatitis B Market Dynamics: Hepatitis B market drivers and Hepatitis B market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hepatitis B Unmet Needs, KOL's views, Analyst's views, Hepatitis B Market Access and Reimbursement

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.